Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II/III XIRIUS study of cotoretigene toliparvovec in XLPR does not meet primary endpoint

May 17, 2021

Regeneron's REGN-7483F Mini-VEGF-Trap could be a next-generation VEGF inhibitor

May 17, 2021

Osmol initiates IND-enabling studies of OSM-0205 for prevention of CIPN

May 17, 2021

Phase Ib/IIa trial evaluates tigilanol tiglate with pembrolizumab in advanced melanoma

May 14, 2021

R0.6C vaccine candidate for malaria enters first-in-human study

May 14, 2021

Astellas studies ASP-0367 in phase II/III for primary mitochondrial myopathy

May 14, 2021

Preliminary clinical data of highly purified chimeric antigen receptor T-cell therapy targeting CD19

May 14, 2021

TG Therapeutics initiates phase Ib study of TG-1801 in B-cell lymphoma or CLL

May 14, 2021

Enrollment opens in phase I/II study of BLU-945 in patients with EGFR mutant NSCLC

May 14, 2021

Stem cell lentiviral therapy restores neuromuscular symptoms in models of Pompe disease

May 14, 2021

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...